GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imago BioSciences Inc (NAS:IMGO) » Definitions » PE Ratio without NRI

Imago BioSciences (Imago BioSciences) PE Ratio without NRI : At Loss (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Imago BioSciences PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-05-05), Imago BioSciences's share price is $36.01. Imago BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.84. Therefore, Imago BioSciences's PE Ratio without NRI for today is At Loss.

Imago BioSciences's EPS without NRI for the three months ended in Sep. 2022 was $-0.50. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.84.

As of today (2024-05-05), Imago BioSciences's share price is $36.01. Imago BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.84. Therefore, Imago BioSciences's PE Ratio for today is At Loss.

Imago BioSciences's EPS (Diluted) for the three months ended in Sep. 2022 was $-0.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.84.

Imago BioSciences's EPS (Basic) for the three months ended in Sep. 2022 was $-0.50. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was $-1.84.


Imago BioSciences PE Ratio without NRI Historical Data

The historical data trend for Imago BioSciences's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imago BioSciences PE Ratio without NRI Chart

Imago BioSciences Annual Data
Trend Dec19 Dec20 Dec21
PE Ratio without NRI
N/A N/A At Loss

Imago BioSciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Imago BioSciences's PE Ratio without NRI

For the Biotechnology subindustry, Imago BioSciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imago BioSciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imago BioSciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Imago BioSciences's PE Ratio without NRI falls into.



Imago BioSciences PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Imago BioSciences's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=36.01/-1.840
=-19.57(At Loss)

Imago BioSciences's Share Price of today is $36.01.
Imago BioSciences's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Imago BioSciences  (NAS:IMGO) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Imago BioSciences PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Imago BioSciences's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Imago BioSciences (Imago BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA, 94080
Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).
Executives
Laura G. Eichorn officer: Chief Operating Officer IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Michael Arenberg officer: See Remarks 10260 BUBB ROAD, CUPERTINO CA 95014
Hugh Jr Rienhoff director, officer: Chief Executive Officer IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Amy E. Tapper officer: See Remarks IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Jennifer Peppe officer: See Remarks IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Hsiangyi Chiang officer: Senior Vice President Finance C/O IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Ventures Iii Gp, L.p. 10 percent owner C/O CLARUS VENTURES, 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings Ii L.p. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142

Imago BioSciences (Imago BioSciences) Headlines

From GuruFocus